Creative Global Technology vs AsiaStrategy
CGTL and SORA side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGTL and SORA compare
AsiaStrategy grew revenue faster over the last twelve months (−37.7% versus −40.6% for Creative Global Technology).
AsiaStrategy keeps more of each dollar of sales as profit, with a net margin of 112% compared with −63.2% at Creative Global Technology.
AsiaStrategy scores higher on the StockData Score (6 against 5 for Creative Global Technology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGTL | SORA |
|---|---|---|
| Size and price | ||
| Share price | $2.49 | $2.20 |
| Change, 1 year | −73.9% | −45.8% |
| Beta (5Y) | −0.47 | 2.13 |
| Employees | 12 | 7 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −40.6% | −37.7% (better) |
| Net income growth (TTM) | −412% | – |
| EPS growth (TTM) | −371% | – |
| Profitability | ||
| Gross margin | 10.8% (better) | 3.5% |
| Operating margin | −62.2% | −14.3% (better) |
| Net margin | −63.2% | 112% (better) |
| FCF margin | – | −39.4% |
| Return on equity | −96.5% | 81.8% (better) |
| Return on invested capital | −77.7% | −47.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.03 (better) |
| Interest coverage | – | −5.3× |
| Current ratio | 46.70 (better) | 17.06 |
| Piotroski F-score | 3 | 4 (better) |
| Ownership | ||
| Held by institutions | 0.10% | 0.14% |
| Held by insiders | 0.00% | 58.1% |
| Short interest, % of float | 0.02% | 0.79% |
Go deeper
- CGTL stock overview
- CGTL income statement
- CGTL valuation and score
- SORA stock overview
- SORA income statement
- SORA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.